Antenatal IVIG therapy is often employed to address conditions such as alloimmune thrombocytopenia, where the mother's immune system attacks the fetal platelets, causing low platelet counts. It is also used in certain cases of hemolytic disease of the fetus and newborn (HDFN), where the mother's antibodies target fetal red blood cells, leading to anemia. Additionally, IVIG can be considered for the prevention of congenital infections such as cytomegalovirus (CMV) and parvovirus B19.
